权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Patho-Genetic Analysis of Invasive Mucinous Adenocarcinoma of the Lung

肺侵袭性粘液性腺癌的病理遗传学分析

基本信息

批准号：
10596503
负责人：
Yutaka Maeda
金额：
$ 61.93万
依托单位：
CINCINNATI CHILDRENS HOSP MED CTR
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-04-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10596503
关键词：
3-Dimensional Adenocarcinoma Appendix Adenocarcinoma Biological Markers Biology Boston Cancer Etiology Cancer Patient Candidate Disease Gene Cell Communication Cell Line Cells Cellular Morphology Cessation of life Cities Classification Data Development Diagnosis Epidermal Growth Factor Receptor Europe Evaluation Gastrointestinal tract structure Gene Expression Genes Genetic Goals Goblet Cells Growth HNF4A gene Heterogeneity Histology Human Immune Immunohistochemistry Immunotherapy In Vitro Iowa Japan KRAS2 gene KRASG12D Knowledge Lung Lung Adenocarcinoma Lung Neoplasms Malignant - descriptor Malignant Neoplasms Malignant neoplasm of lung Malignant neoplasm of pancreas Metastatic Neoplasm to the Lung Mission Molecular Molecular Analysis Morphology Mucinous Mucinous Neoplasm Mucins Mucous body substance Mutation New York City Nuclear Receptors Oncologist Organ Organoids Outcome Pancreatic Adenocarcinoma Papillary Pathologic Pathologist Pathway interactions Patients Pharmaceutical Preparations Public Health Reporting Research Research Personnel Sodium Chloride Solid Specimen Stromal Cells Surgeon Testing Therapeutic Therapeutic antibodies United States National Institutes of Health autocrine biomarker identification cell type diagnostic biomarker driver mutation effective therapy gastrointestinal genetic analysis genetic signature human disease in vivo innovation mRNA sequencing molecular targeted therapies mouse model neoplastic cell new technology new therapeutic target next generation sequencing novel therapeutics paracrine programmed cell death ligand 1 programs single-cell RNA sequencing small molecular inhibitor small molecule therapeutic biomarker therapeutic target tumor tumor microenvironment

项目摘要

Despite recent progress in the development of molecularly-targeted therapy and immunotherapy, lung cancer is still the leading cause of cancer death since such therapies are not applicable for more than half of lung cancer patients. Lung adenocarcinoma is the major pathological type of lung cancer. Lung adenocarcinoma has been further subdivided based on both genetic alterations (e.g., KRAS or EGFR mutations and ALK fusions) and differentiation state (including histopathologic subtypes such as acinar, lepidic, papillary, solid and mucinous). In most cases, such genetic alterations do not strictly correlate with the histopathologic subtypes of lung adenocarcinomas. However, genetic and molecular pathways that lead to the development of invasive mucinous adenocarcinoma of the lung (IMA) have been revealed by our team and others in the past several years (e.g., HNF4A pathway), suggesting that such molecular pathways can be targeted to treat IMA for which there is currently no effective therapy. Notably, the histology of IMA resembles that of mucus-producing cancers found in the gastrointestinal tract (e.g., pancreatic cancer), which hampers efforts to properly diagnose IMA from lung metastases originating from other mucus-producing organs. A biomarker to distinguish IMA from lung metastases has not been established. Our long-term goal is to identify a therapy for IMA. The objective here is to 1) determine whether HNF4A and its downstream genes that are specifically expressed in IMA but not in normal lung can be therapeutic targets for IMA and 2) comprehensively identify therapeutic targets and biomarkers using novel technologies such as single-cell mRNA-seq and 3D tumoroid (organoid) culture with a large number of IMA specimens (>200). The central hypothesis is that IMA is driven by distinct molecular pathways that can be therapeutically targeted. The rationale is based on our previous and preliminary studies indicating that 1) the HNF4A pathway is required for the growth of IMA and 2) such a pathway creates a specific tumor microenvironment that influences tumor-associated cells, which presents specific therapeutic targets and biomarkers. This hypothesis will be tested in the following specific aims: 1) determine whether HNF4A and/or its downstream genes can be therapeutic targets for IMA, 2) analyze the heterogeneity of IMA at a single-cell level, and 3) discover diagnostic biomarkers for IMA. The approach is innovative because it will focus on molecular pathways that have not been explored as therapeutic targets for IMA. The proposed research will: 1) utilize model mice for IMA (GEMM and PDX) and human specimens of IMA and lung metastases and 2) determine whether small molecular inhibitors and therapeutic antibodies can reduce the growth of IMA. The proposed research is significant because our team, comprised of a number of IMA researchers from several institutes, will bring their knowledge and expertise together to develop a novel therapy for IMA.

尽管最近在分子靶向治疗和免疫治疗方面取得了进展，但肺癌仍然是一种恶性肿瘤